 | • レポートコード：D0804-09381 • 出版社/出版日：GlobalInfoResearch / 2020年7月28日 ※2025年版があります。お問い合わせください。 • レポート形態：英語、PDF、100ページ • 納品方法：Eメール • 産業分類：医薬品・治療 |
| Single User | ￥487,200 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥730,800 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥974,400 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、経口血糖降下薬及びインスリン類似体の世界市場を広く調査・分析し、今後の市場展望をまとめております。経口血糖降下薬及びインスリン類似体の種類別市場規模（インスリン分泌促進薬、α-グルコシダーゼ阻害剤、インスリン抵抗性改善薬）、用途別市場規模（病院、ドラッグストア、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・メーカー情報（販売量、市場シェア、製品概要、SWOT分析）：Sanofi-Aventis、Jiangsu Wanbang、Novo Nordisk、Ganlee、United Laboratory、Biocon、Tonghua Dongbao、Eli Lilly ・地域別グローバル市場分析 2015年-2020年 ・経口血糖降下薬及びインスリン類似体の北米市場（アメリカ、カナダ、メキシコ） ・経口血糖降下薬及びインスリン類似体のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・経口血糖降下薬及びインスリン類似体のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・経口血糖降下薬及びインスリン類似体の南米市場（ブラジル、アルゼンチン） ・経口血糖降下薬及びインスリン類似体の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：インスリン分泌促進薬、α-グルコシダーゼ阻害剤、インスリン抵抗性改善薬 ・用途別分析：病院、ドラッグストア、その他 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The global Oral Hypoglycemic Agents and Insulin Analogues market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Oral Hypoglycemic Agents and Insulin Analogues market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Oral Hypoglycemic Agents and Insulin Analogues market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Oral Hypoglycemic Agents and Insulin Analogues market has been segmented into
Insulin Secretagogues
Alpha-glucosidase Inhibitors
Insulin Sensitizers
By Application, Oral Hypoglycemic Agents and Insulin Analogues has been segmented into:
Hospitals
Drug Store
Others
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Oral Hypoglycemic Agents and Insulin Analogues market presented in the report. This section sheds light on the sales growth of different regional and country-level Oral Hypoglycemic Agents and Insulin Analogues markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Oral Hypoglycemic Agents and Insulin Analogues market.
The report offers in-depth assessment of the growth and other aspects of the Oral Hypoglycemic Agents and Insulin Analogues market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Oral Hypoglycemic Agents and Insulin Analogues Market Share Analysis
Oral Hypoglycemic Agents and Insulin Analogues competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Oral Hypoglycemic Agents and Insulin Analogues sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Oral Hypoglycemic Agents and Insulin Analogues sales, revenue and market share for each player covered in this report.
The major players covered in Oral Hypoglycemic Agents and Insulin Analogues are:
Sanofi-Aventis
Jiangsu Wanbang
Novo Nordisk
Ganlee
United Laboratory
Biocon
Tonghua Dongbao
Eli Lilly
Among other players domestic and global, Oral Hypoglycemic Agents and Insulin Analogues market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Oral Hypoglycemic Agents and Insulin Analogues product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Oral Hypoglycemic Agents and Insulin Analogues, with price, sales, revenue and global market share of Oral Hypoglycemic Agents and Insulin Analogues in 2018 and 2019.
Chapter 3, the Oral Hypoglycemic Agents and Insulin Analogues competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Oral Hypoglycemic Agents and Insulin Analogues breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Oral Hypoglycemic Agents and Insulin Analogues market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Oral Hypoglycemic Agents and Insulin Analogues sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 Oral Hypoglycemic Agents and Insulin Analogues Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Insulin Secretagogues
1.2.3 Alpha-glucosidase Inhibitors
1.2.4 Insulin Sensitizers
1.3 Market Analysis by Application
1.3.1 Overview: Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals
1.3.3 Drug Store
1.3.4 Others
1.4 Overview of Global Oral Hypoglycemic Agents and Insulin Analogues Market
1.4.1 Global Oral Hypoglycemic Agents and Insulin Analogues Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Sanofi-Aventis
2.1.1 Sanofi-Aventis Details
2.1.2 Sanofi-Aventis Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Sanofi-Aventis SWOT Analysis
2.1.4 Sanofi-Aventis Product and Services
2.1.5 Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Jiangsu Wanbang
2.2.1 Jiangsu Wanbang Details
2.2.2 Jiangsu Wanbang Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Jiangsu Wanbang SWOT Analysis
2.2.4 Jiangsu Wanbang Product and Services
2.2.5 Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Novo Nordisk
2.3.1 Novo Nordisk Details
2.3.2 Novo Nordisk Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Novo Nordisk SWOT Analysis
2.3.4 Novo Nordisk Product and Services
2.3.5 Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Ganlee
2.4.1 Ganlee Details
2.4.2 Ganlee Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Ganlee SWOT Analysis
2.4.4 Ganlee Product and Services
2.4.5 Ganlee Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 United Laboratory
2.5.1 United Laboratory Details
2.5.2 United Laboratory Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 United Laboratory SWOT Analysis
2.5.4 United Laboratory Product and Services
2.5.5 United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Biocon
2.6.1 Biocon Details
2.6.2 Biocon Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Biocon SWOT Analysis
2.6.4 Biocon Product and Services
2.6.5 Biocon Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 Tonghua Dongbao
2.7.1 Tonghua Dongbao Details
2.7.2 Tonghua Dongbao Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Tonghua Dongbao SWOT Analysis
2.7.4 Tonghua Dongbao Product and Services
2.7.5 Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.8 Eli Lilly
2.8.1 Eli Lilly Details
2.8.2 Eli Lilly Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Eli Lilly SWOT Analysis
2.8.4 Eli Lilly Product and Services
2.8.5 Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Oral Hypoglycemic Agents and Insulin Analogues Manufacturer Market Share in 2019
3.3.2 Top 6 Oral Hypoglycemic Agents and Insulin Analogues Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Market Share by Regions
4.1.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales and Market Share by Regions (2015-2020)
4.1.2 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue and Market Share by Regions (2015-2020)
4.2 North America Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020)
4.3 Europe Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020)
4.5 South America Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Market Share by Country
5.1.1 North America Oral Hypoglycemic Agents and Insulin Analogues Sales and Market Share by Country (2015-2020)
5.1.2 North America Oral Hypoglycemic Agents and Insulin Analogues Revenue and Market Share by Country (2015-2020)
5.2 United States Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020)
5.3 Canada Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020)
5.4 Mexico Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Market Share by Country
6.1.1 Europe Oral Hypoglycemic Agents and Insulin Analogues Sales and Market Share by Country (2015-2020)
6.1.2 Europe Oral Hypoglycemic Agents and Insulin Analogues Revenue and Market Share by Country (2015-2020)
6.2 Germany Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020)
6.3 UK Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020)
6.4 France Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020)
6.5 Russia Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020)
6.6 Italy Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Revenue and Market Share by Regions (2015-2020)
7.2 China Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020)
7.3 Japan Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020)
7.4 Korea Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020)
7.5 India Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020)
7.7 Australia Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Market Share by Country
8.1.1 South America Oral Hypoglycemic Agents and Insulin Analogues Sales and Market Share by Country (2015-2020)
8.1.2 South America Oral Hypoglycemic Agents and Insulin Analogues Revenue and Market Share by Country (2015-2020)
8.2 Brazil Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020)
8.3 Argentina Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020)
9.3 Turkey Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020)
9.4 Egypt Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020)
9.5 South Africa Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales and Market Share by Type (2015-2020)
10.2 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue and Market Share by Type (2015-2020)
10.3 Global Oral Hypoglycemic Agents and Insulin Analogues Price by Type (2015-2020)
11 Global Oral Hypoglycemic Agents and Insulin Analogues Market Segment by Application
11.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application (2015-2020)
11.2 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Application (2015-2020)
11.3 Global Oral Hypoglycemic Agents and Insulin Analogues Price by Application (2015-2020)
12 Market Forecast
12.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Growth Rate (2021-2025)
12.2 Oral Hypoglycemic Agents and Insulin Analogues Market Forecast by Regions (2021-2025)
12.2.1 North America Oral Hypoglycemic Agents and Insulin Analogues Market Forecast (2021-2025)
12.2.2 Europe Oral Hypoglycemic Agents and Insulin Analogues Market Forecast (2021-2025)
12.2.3 Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Market Forecast (2021-2025)
12.2.4 South America Oral Hypoglycemic Agents and Insulin Analogues Market Forecast (2021-2025)
12.2.5 Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Market Forecast (2021-2025)
12.3 Oral Hypoglycemic Agents and Insulin Analogues Market Forecast by Type (2021-2025)
12.3.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales Forecast by Type (2021-2025)
12.3.2 Global Oral Hypoglycemic Agents and Insulin Analogues Market Share Forecast by Type (2021-2025)
12.4 Oral Hypoglycemic Agents and Insulin Analogues Market Forecast by Application (2021-2025)
12.4.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales Forecast by Application (2021-2025)
12.4.2 Global Oral Hypoglycemic Agents and Insulin Analogues Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Oral Hypoglycemic Agents and Insulin Analogues by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. Sanofi-Aventis Basic Information, Manufacturing Base and Competitors
Table 8. Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Major Business
Table 9. Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Total Revenue (USD Million) (2017-2018)
Table 10. Sanofi-Aventis SWOT Analysis
Table 11. Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Product and Services
Table 12. Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Jiangsu Wanbang Basic Information, Manufacturing Base and Competitors
Table 14. Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Major Business
Table 15. Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Total Revenue (USD Million) (2017-2018)
Table 16. Jiangsu Wanbang SWOT Analysis
Table 17. Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Product and Services
Table 18. Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. Novo Nordisk Basic Information, Manufacturing Base and Competitors
Table 20. Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Major Business
Table 21. Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Total Revenue (USD Million) (2017-2018)
Table 22. Novo Nordisk SWOT Analysis
Table 23. Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Product and Services
Table 24. Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. Ganlee Basic Information, Manufacturing Base and Competitors
Table 26. Ganlee Oral Hypoglycemic Agents and Insulin Analogues Major Business
Table 27. Ganlee Oral Hypoglycemic Agents and Insulin Analogues Total Revenue (USD Million) (2017-2018)
Table 28. Ganlee SWOT Analysis
Table 29. Ganlee Oral Hypoglycemic Agents and Insulin Analogues Product and Services
Table 30. Ganlee Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. United Laboratory Basic Information, Manufacturing Base and Competitors
Table 32. United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Major Business
Table 33. United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Total Revenue (USD Million) (2017-2018)
Table 34. United Laboratory SWOT Analysis
Table 35. United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Product and Services
Table 36. United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. Biocon Basic Information, Manufacturing Base and Competitors
Table 38. Biocon Oral Hypoglycemic Agents and Insulin Analogues Major Business
Table 39. Biocon Oral Hypoglycemic Agents and Insulin Analogues Total Revenue (USD Million) (2017-2018)
Table 40. Biocon SWOT Analysis
Table 41. Biocon Oral Hypoglycemic Agents and Insulin Analogues Product and Services
Table 42. Biocon Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 43. Tonghua Dongbao Basic Information, Manufacturing Base and Competitors
Table 44. Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Major Business
Table 45. Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Total Revenue (USD Million) (2017-2018)
Table 46. Tonghua Dongbao SWOT Analysis
Table 47. Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Product and Services
Table 48. Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 49. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 50. Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Major Business
Table 51. Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Total Revenue (USD Million) (2017-2018)
Table 52. Eli Lilly SWOT Analysis
Table 53. Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Product and Services
Table 54. Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 55. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Manufacturer (2018-2019) (K MT)
Table 56. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Manufacturer (2018-2019) (USD Million)
Table 57. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Regions (2015-2020) (K MT)
Table 58. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Regions (2015-2020)
Table 59. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Regions (2015-2020) (USD Million)
Table 60. North America Oral Hypoglycemic Agents and Insulin Analogues Sales by Countries (2015-2020) (K MT)
Table 61. North America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Countries (2015-2020)
Table 62. North America Oral Hypoglycemic Agents and Insulin Analogues Revenue by Countries (2015-2020) (USD Million)
Table 63. North America Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Countries (2015-2020)
Table 64. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales by Countries (2015-2020) (K MT)
Table 65. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Countries (2015-2020)
Table 66. Europe Oral Hypoglycemic Agents and Insulin Analogues Revenue by Countries (2015-2020) (USD Million)
Table 67. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales by Regions (2015-2020) (K MT)
Table 68. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Regions (2015-2020)
Table 69. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Revenue by Regions (2015-2020) (USD Million)
Table 70. South America Oral Hypoglycemic Agents and Insulin Analogues Sales by Countries (2015-2020) (K MT)
Table 71. South America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Countries (2015-2020)
Table 72. South America Oral Hypoglycemic Agents and Insulin Analogues Revenue by Countries (2015-2020) (USD Million)
Table 73. South America Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Countries (2015-2020)
Table 74. Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Sales by Countries (2015-2020) (K MT)
Table 75. Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Countries (2015-2020)
Table 76. Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Revenue by Countries (2015-2020) (USD Million)
Table 77. Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Countries (2015-2020)
Table 78. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2015-2020) (K MT)
Table 79. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Share by Type (2015-2020)
Table 80. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Type (2015-2020) (USD Million)
Table 81. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Share by Type (2015-2020)
Table 82. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2015-2020) (K MT)
Table 83. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Share by Application (2015-2020)
Table 84. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Forecast by Regions (2021-2025) (K MT)
Table 85. Global Oral Hypoglycemic Agents and Insulin Analogues Market Share Forecast by Regions (2021-2025)
Table 86. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Forecast by Type (2021-2025) (K MT)
Table 87. Global Oral Hypoglycemic Agents and Insulin Analogues Market Share Forecast by Type (2021-2025)
Table 88. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Forecast by Application (2021-2025)
Table 89. Global Oral Hypoglycemic Agents and Insulin Analogues Market Share Forecast by Application (2021-2025)
Table 90. Direct Channel Pros & Cons
Table 91. Indirect Channel Pros & Cons
Table 92. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Oral Hypoglycemic Agents and Insulin Analogues Picture
Figure 2. Global Sales Market Share of Oral Hypoglycemic Agents and Insulin Analogues by Type in 2019
Figure 3. Insulin Secretagogues Picture
Figure 4. Alpha-glucosidase Inhibitors Picture
Figure 5. Insulin Sensitizers Picture
Figure 6. Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application in 2018
Figure 7. Hospitals Picture
Figure 8. Drug Store Picture
Figure 9. Others Picture
Figure 10. Global Oral Hypoglycemic Agents and Insulin Analogues Market Status and Outlook (2015-2025) (USD Million)
Figure 11. United States Oral Hypoglycemic Agents and Insulin Analogues Revenue (Value) and Growth Rate (2015-2025)
Figure 12. Canada Oral Hypoglycemic Agents and Insulin Analogues Revenue (Value) and Growth Rate (2015-2025)
Figure 13. Mexico Oral Hypoglycemic Agents and Insulin Analogues Revenue (Value) and Growth Rate (2015-2025)
Figure 14. Germany Oral Hypoglycemic Agents and Insulin Analogues Revenue (Value) and Growth Rate (2015-2025)
Figure 15. France Oral Hypoglycemic Agents and Insulin Analogues Revenue (Value) and Growth Rate (2015-2025)
Figure 16. UK Oral Hypoglycemic Agents and Insulin Analogues Revenue (Value) and Growth Rate (2015-2025)
Figure 17. Russia Oral Hypoglycemic Agents and Insulin Analogues Revenue (Value) and Growth Rate (2015-2025)
Figure 18. Italy Oral Hypoglycemic Agents and Insulin Analogues Revenue (Value) and Growth Rate (2015-2025)
Figure 19. China Oral Hypoglycemic Agents and Insulin Analogues Revenue (Value) and Growth Rate (2015-2025)
Figure 20. Japan Oral Hypoglycemic Agents and Insulin Analogues Revenue (Value) and Growth Rate (2015-2025)
Figure 21. Korea Oral Hypoglycemic Agents and Insulin Analogues Revenue (Value) and Growth Rate (2015-2025)
Figure 22. India Oral Hypoglycemic Agents and Insulin Analogues Revenue (Value) and Growth Rate (2015-2025)
Figure 23. Southeast Asia Oral Hypoglycemic Agents and Insulin Analogues Revenue (Value) and Growth Rate (2015-2025)
Figure 24. Australia Oral Hypoglycemic Agents and Insulin Analogues Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 25. Brazil Oral Hypoglycemic Agents and Insulin Analogues Revenue (Value) and Growth Rate (2015-2025)
Figure 26. Egypt Oral Hypoglycemic Agents and Insulin Analogues Revenue (Value) and Growth Rate (2015-2025)
Figure 27. Saudi Arabia Oral Hypoglycemic Agents and Insulin Analogues Revenue (Value) and Growth Rate (2015-2025)
Figure 28. South Africa Oral Hypoglycemic Agents and Insulin Analogues Revenue (Value) and Growth Rate (2015-2025)
Figure 29. Turkey Oral Hypoglycemic Agents and Insulin Analogues Revenue (Value) and Growth Rate (2015-2025)
Figure 30. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Manufacturer in 2019
Figure 31. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Manufacturer in 2019
Figure 32. Top 3 Oral Hypoglycemic Agents and Insulin Analogues Manufacturer (Revenue) Market Share in 2019
Figure 33. Top 6 Oral Hypoglycemic Agents and Insulin Analogues Manufacturer (Revenue) Market Share in 2019
Figure 34. Key Manufacturer Market Share Trend
Figure 35. Global Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020) (K MT)
Figure 36. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue and Growth Rate (2015-2020) (USD Million)
Figure 37. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Regions (2015-2020)
Figure 38. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Regions in 2018
Figure 39. North America Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020)
Figure 40. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020)
Figure 41. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020)
Figure 42. South America Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020)
Figure 43. Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020)
Figure 44. North America Oral Hypoglycemic Agents and Insulin Analogues Revenue and Growth Rate (2015-2020) (USD Million)
Figure 45. North America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Countries (2015-2020)
Figure 46. North America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Countries in 2018
Figure 47. North America Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 48. North America Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Countries in 2018
Figure 49. United States Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020) (K MT)
Figure 50. Canada Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020) (K MT)
Figure 51. Mexico Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020) (K MT)
Figure 52. Europe Oral Hypoglycemic Agents and Insulin Analogues Revenue and Growth Rate (2015-2020) (USD Million)
Figure 53. Europe Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Countries (2015-2020)
Figure 54. Europe Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Countries in 2019
Figure 55. Germany Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020) (K MT)
Figure 56. UK Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020) (K MT)
Figure 57. France Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020) (K MT)
Figure 58. Russia Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020) (K MT)
Figure 59. Italy Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020) (K MT)
Figure 60. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Revenue and Growth Rate (2015-2020) (USD Million)
Figure 61. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Regions 2019
Figure 62. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Regions 2019
Figure 63. China Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020) (K MT)
Figure 64. Japan Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020) (K MT)
Figure 65. Korea Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020) (K MT)
Figure 66. India Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020) (K MT)
Figure 67. Southeast Asia Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020) (K MT)
Figure 68. South America Oral Hypoglycemic Agents and Insulin Analogues Revenue and Growth Rate (2015-2020) (USD Million)
Figure 69. South America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Countries in 2019
Figure 70. South America Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Countries in 2019
Figure 71. Brazil Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020) (K MT)
Figure 72. Argentina Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020) (K MT)
Figure 73. Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Revenue and Growth Rate (2015-2020) (USD Million)
Figure 74. Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Countries in 2019
Figure 75. Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Countries (2015-2020)
Figure 76. Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Countries in 2019
Figure 77. Saudi Arabia Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020) (K MT)
Figure 78. Egypt Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020) (K MT)
Figure 79. Turkey Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020) (K MT)
Figure 80. South Africa Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2020) (K MT)
Figure 81. Global Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2021-2025) (K MT)
Figure 82. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue and Growth Rate (2021-2025) (USD Million)
Figure 83. North America Sales Oral Hypoglycemic Agents and Insulin Analogues Market Forecast (2021-2025) (K MT)
Figure 84. Europe Sales Oral Hypoglycemic Agents and Insulin Analogues Market Forecast (2021-2025) (K MT)
Figure 85. Asia-Pacific Sales Oral Hypoglycemic Agents and Insulin Analogues Market Forecast (2021-2025) (K MT)
Figure 86. South America Sales Oral Hypoglycemic Agents and Insulin Analogues Market Forecast (2021-2025) (K MT)
Figure 87. Middle East & Africa Sales Oral Hypoglycemic Agents and Insulin Analogues Market Forecast (2021-2025) (K MT)
Figure 88. Sales Channel: Direct Channel vs Indirect Channel
経口血糖降下薬の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The Oral Hypoglycemic Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimizatio…- 経口血糖降下薬の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The Oral Hypoglycemic Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimizatio…
- スマートインスリンペンの世界市場 2020年：企業別・地域別・種類別・用途別市場予測 Market Overview The Smart Insulin Pens market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, tr…
- 磁気共鳴画像（MRI）造影剤の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Magnetic Resonance Imaging (MRI) Contrast Agents market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. …
- 組織シール剤・止血剤の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The Tissue Sealing Agents and Hemostasis market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chai…